Vizsgálati helyszín
Klinische Forschung Hannover-Mitte GmbH
Hanover, 30159, NémetországMég nincs intézményhez kötve
- 12futó vizsgálat
- 16lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 28 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis20 vizsgálat
- 2. fázis4 vizsgálat
- 1. fázis2 vizsgálat
- 4. fázis2 vizsgálat
- Állapot
- Lezárult15 vizsgálat
- Toboroz8 vizsgálat
- Fut, nem toboroz3 vizsgálat
- Még nem toboroz1 vizsgálat
- Leállították1 vizsgálat
- Fő szponzor
- AbbVie2 vizsgálat
- Ascletis Pharma (China) Co. Ltd.2 vizsgálat
- AstraZeneca2 vizsgálat
- Dr. Willmar Schwabe GmbH & Co. KG2 vizsgálat
- ModernaTX, Inc.2 vizsgálat
- és még 17
Futó vizsgálatok
Toboroz
A Study to evaluate effect of AZD6234 in adult participants with Type 2 Diabetes Mellitus and obesity or overweight
2025-524616-11-00· 3. fázis· AstraZeneca AB· Forrás
Még nem toboroz
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CD388, a Novel Long-Acting Antiviral Conjugate, for the Prevention of Influenza in Adults and Adolescents at Higher Risk of Developing Influenza Complications
2026-527531-33-00· 3. fázis· Cidara Therapeutics Inc.· Forrás
Toboroz
Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Weight-Related Comorbidities
2026-526172-23-00· 3. fázis· Ascletis Pharma (China) Co. Ltd.· Forrás
Toboroz
Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Type 2 Diabetes Mellitus
2026-526336-39-00· 3. fázis· Ascletis Pharma (China) Co. Ltd.· Forrás
Toboroz
A study on the efficacy of a vaccine against influenza in adults ≥65 years of age
2026-526682-14-00· 3. fázis· GlaxoSmithKline Biologicals· Forrás
Toboroz
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Silexan® in mild to moderate major depressive disorder
2025-521744-37-00· 3. fázis· Dr. Willmar Schwabe GmbH & Co. KG· Forrás
Fut, nem toboroz
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
NCT07153471· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370· 3. fázis· Boehringer Ingelheim· Forrás
Fut, nem toboroz
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
NCT06154837· 1. fázis· GlaxoSmithKline· Forrás
Toboroz
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200· 3. fázis· Anthos Therapeutics, Inc.· Forrás
Toboroz
Randomized, double-blind, placebo-controlled, multi-centre trial to evaluate the efficacy, safety and tolerability of oral treatment with living bacteria of E. coli DSM 17252 (Symbioflor®2) in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D)
2024-512104-19-00· 4. fázis· SymbioPharm GmbH· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A trial to find the effect of Ginkgo biloba extract EGb 761® and how safe it is in participants with cognitive impairment associated with post COVID-19 syndrome
2024-517199-39-00· 2. fázis· Dr. Willmar Schwabe GmbH & Co. KG· Forrás
Lezárult
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
NCT06602024· 3. fázis· ModernaTX, Inc.· Forrás
Lezárult
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis
2023-504564-42-00· 2. fázis· Anaptysbio Inc.· Forrás
Lezárult
A proof of concept and dose-finding study of XXB750 in patients with heart failure
2023-504678-39-00· 2. fázis· Novartis Pharma AG· Forrás
Lezárult
A trial of prednisolone in combination with SPI-62 in participants with polymyalgia rheumatica (PMR)
2023-507721-41-00· 1. fázis· Sparrow Pharmaceuticals Inc.· Forrás
Lezárult
The Celljuvant study, A phase 3 Immunogenicity and Safety Study of aQIVc HD Vaccine in Adults aged 50 years and older.
2023-503763-42-00· 3. fázis· Seqirus UK Limited· Forrás
Lezárult
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older
NCT06015282· 3. fázis· Seqirus· Forrás
Lezárult
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
NCT05748483· 3. fázis· AbbVie· Forrás
Lezárult
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
NCT06040086· 3. fázis· AstraZeneca· Forrás
Lezárult
Efficacy and Tolerability of Tasipimidine in Sleepless Patients
NCT06956495· 2. fázis· Orion Corporation, Orion Pharma· Forrás
Fut, nem toboroz
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
NCT05968430· 3. fázis· Mineralys Therapeutics Inc.· Forrás
Lezárult
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older
NCT05566639· 3. fázis· ModernaTX, Inc.· Forrás
Lezárult
Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol,is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.
2024-511263-28-00· 4. fázis· Novartis Pharma AG· Forrás
Lezárult
A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia
NCT05079919· 3. fázis· Ionis Pharmaceuticals, Inc.· Forrás
Lezárult
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
NCT04686136· 3. fázis· AbbVie· Forrás
Leállították
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
NCT04241068· 3. fázis· Biogen· Forrás
Hibát jelzek